Guidance, NICE advice and quality standards in development | Guidance

Showing 221 to 230 of 375

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]	Technology appraisal guidance	TBC
NY-ESO-1 T-cells for treating synovial sarcoma [ID1286]	Technology appraisal guidance	TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]	Technology appraisal guidance	TBC
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]	Technology appraisal guidance	14 October 2026
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]	Technology appraisal guidance	TBC
Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management	NICE guideline	16 February 2027
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]	Technology appraisal guidance	TBC
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]	Technology appraisal guidance	19 August 2026
Omburtamab for treating relapsed neuroblastoma [ID1664]	Technology appraisal guidance	TBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]	Technology appraisal guidance	TBC